Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Center for Cancer Registries, Center for Cancer Control and Information Service, National Cancer Center, Tokyo, Japan.
Int J Urol. 2021 Aug;28(8):814-819. doi: 10.1111/iju.14583. Epub 2021 May 19.
To examine the discrepancy between clinical and pathological T stages in patients with urothelial carcinoma of the upper urinary tract treated with radical surgery, and to compare them with the corresponding discrepancy in urothelial carcinoma of the bladder.
We used the Hospital-Based Cancer Registry data in Japan to extract urothelial carcinoma of the bladder cases (n = 3747) and urothelial carcinoma of the upper urinary tract cases (n = 6831), including urothelial carcinoma of the renal pelvis (n = 3295) and urothelial carcinoma of the ureter (n = 3536) with cT1-4N0M0 diagnosed in 2012-2015, histologically confirmed, and treated with radical surgery without chemotherapy or radiotherapy. We compared the T-stage discrepancy among different tumor locations.
The proportions of overall T-stage discrepancy in the urothelial carcinoma of the renal pelvis (40.8%) and urothelial carcinoma of the ureter (42.9%) groups tended to be higher compared with that in the urothelial carcinoma of the bladder (38.8%) group. The upstaging rate from clinical non-muscle-invasive cancer (≤cT1) to pathological muscle-invasive cancer (≥pT2) was significantly higher in the urothelial carcinoma of the renal pelvis and urothelial carcinoma of the ureter groups compared with the urothelial carcinoma of the bladder group (P = 0.002, P < 0.0001, respectively). Upstaging from clinical organ-confined disease (≤cT2) to pathological non-organ-confined disease (≥pT3) was significantly more frequent in the urothelial carcinoma of the renal pelvis (27.8%, P < 0.0001) and urothelial carcinoma of the ureter (22.3%, P < 0.0001) groups compared with the urothelial carcinoma of the bladder (17.8%) group.
Discrepancy in T staging is significantly higher in patients with urothelial carcinoma of the upper urinary tract compared with those with urothelial carcinoma of the bladder, especially in those with organ-confined disease. As T-stage discrepancy might lead to missed opportunities to carry out perioperative treatment, more accurate diagnostic techniques are required to identify the appropriate urothelial carcinoma candidates for preoperative treatment.
探讨接受根治性手术治疗的上尿路上皮癌患者临床与病理 T 分期之间的差异,并与膀胱癌进行比较。
我们利用日本基于医院的癌症登记数据,提取了 2012-2015 年经病理确诊为 cT1-4N0M0、接受根治性手术而未接受化疗或放疗的膀胱尿路上皮癌(n=3747)和上尿路上皮癌(n=6831)病例,包括肾盂尿路上皮癌(n=3295)和输尿管尿路上皮癌(n=3536)。比较不同肿瘤部位的 T 分期差异。
肾盂尿路上皮癌(40.8%)和输尿管尿路上皮癌(42.9%)组的总体 T 分期差异比例倾向于高于膀胱尿路上皮癌(38.8%)组。与膀胱尿路上皮癌组相比,肾盂尿路上皮癌和输尿管尿路上皮癌组从临床非肌层浸润性癌(≤cT1)到病理肌层浸润性癌(≥pT2)的升级率明显更高(P=0.002,P<0.0001)。从临床局限疾病(≤cT2)到病理非局限疾病(≥pT3)的升级在肾盂尿路上皮癌(27.8%,P<0.0001)和输尿管尿路上皮癌(22.3%,P<0.0001)组明显更频繁,而在膀胱尿路上皮癌组(17.8%)中则不然。
与膀胱尿路上皮癌相比,上尿路上皮癌患者 T 分期的差异明显更大,尤其是局限疾病患者。由于 T 分期的差异可能导致错失围手术期治疗的机会,因此需要更准确的诊断技术来识别适合术前治疗的合适尿路上皮癌患者。